• 1
    Achem SR, DeVault KR. Recent developments in chest pain of undetermined origin. Curr Gastroenterol Rep 2000; 2: 2019.
  • 2
    Fruergaard P, Launbjerg J, Hesse B, et al. The diagnoses of patients admitted with acute chest pain but without myocardial infarction. Eur Heart J 1996; 17: 102834.
  • 3
    Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastrooesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 144856.
  • 4
    Eslick GD, Talley NJ, Young LJ, Jones MP. Non-cardiac chest pain in the population: prevalence and impact. J Gastroenterol Hepatol 1999; 14: A179.
  • 5
    Eslick GD, Talley NJ. Non-cardiac chest pain: squeezing the life out of the Australian healthcare system? Med J Aust 2000; 173: 2334.
  • 6
    Eslick GD, Coulshed DS, Talley NJ. The burden of illness of non-cardiac chest pain. Aliment Pharmacol Ther 2002; 16: 121723.
  • 7
    Lau GK, Hui WM, Lam SK. Life events and daily hassles in patients with atypical chest pain. Am J Gastroenterol 1996; 91: 215762.
  • 8
    Richter JE. Chest pain and gastroesophageal reflux disease. J Clin Gastroenterol 2000; 30(3 Suppl.): S3941.
  • 9
    Potts SG, Bass CM. Psychological morbidity in patients with chest pain and normal or near-normal coronary arteries: a long-term follow-up study. Psychol Med 1995; 25: 33947.
  • 10
    Ho KY, Kang JY, Yeo B, Ng WL. Non-cardiac, non-esophageal chest pain: the relevance of psychological factors. Gut 1998; 43: 10510.
  • 11
    Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 2000; 356: 11549.
  • 12
    Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999; 159: 21618.
  • 13
    Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997; 92: 19972000.
  • 14
    Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-esophageal reflux disease. Scand J Gastroenterol 1998; 33: 1520.
  • 15
    Bate CM, Riley SA, Chapman RW, Durnin AT, Taylor MD. Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13: 5966.
  • 16
    Brun J, Sorngard H. High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-esophageal reflux disease (GERD). Swedish multi-centre group in primary health care. Family Pract 2000; 17: 4014.
  • 17
    Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 395407.
    Direct Link:
  • 18
    Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115: 429.
  • 19
    Fass R, Fennerty MB, Johnson C, Camargo L, Sampliner RE. Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease. J Clin Gastroenterol 1999; 28: 369.
  • 20
    Squillace SJ, Young MF, Sanowski RA. Single dose omeprazole as a test for noncardiac chest pain. Gastroenterology 1993; 104: A197(Abstract).
  • 21
    Ofman JJ, Gralnek IM, Udani J, Fennerty MB, Fass R. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999; 107: 21927.
  • 22
    Hu WHC, Lam KF, Wong YH, et al. The Hong Kong index of dyspepsia: a validated symptom severity questionnaire for patients with dyspepsia. J Gastroenterol Hepatol 2002; 17: 54551.
  • 23
    Johnson LF, DeMeester TR. Twenty-four hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974; 62: 32532.
  • 24
    Hu WHC, Wong NYH, Lai KC, et al. Normal 24 hour ambulatory proximal and distal gastro-oesophageal reflux parameters in Chinese. Hong Kong Med J 2002; 8: 16871.
  • 25
    Richter JE, Bradley LA, DeMeester TR, Wu WC. Normal 24-hr ambulatory esophageal pH values. Influence of study center, pH electrode, age, and gender. Dig Dis Sci 1992; 37: 84956.
  • 26
    Wong WM, Lai KC, Lau CP, et al. Upper gastrointestinal evaluation of Chinese patients with non-cardiac chest pain. Aliment Pharmacol Ther 2002; 16: 46571.
  • 27
    Potts SG, Lewin R, Fox KA, Johnstone EC. Group psychological treatment for chest pain with normal coronary arteries. Q J Med 1999; 92: 816.
  • 28
    Van Peski-Oosterbaan AS, Spinhoven P, Van der Does AJ, Bruschke AV, Rooijmans HG. Cognitive change following cognitive behavioural therapy for non-cardiac chest pain. Psychother Psychosomat 1999; 68: 21420.
  • 29
    Achem SR, Kolts BE, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997; 10: 213845.
  • 30
    Caraco Y, Lagerstrom PO, Wood AJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996; 60: 15767.
  • 31
    Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 102730.
  • 32
    Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001; 69: 15868.
  • 33
    Adachi K, Katsube T, Kawamura A, et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: 125966.
  • 34
    Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 2531.
  • 35
    Ishizaki T, Sohn DR, Kobayashi K, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994; 16: 2145.
  • 36
    Shu Y, Wang LS, Xu ZH, et al. 5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity. J Pharmacol Exp Ther 2000; 295: 84451.
  • 37
    Caraco Y, Wilkinson GR, Wood AJ. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996; 60: 396404.
  • 38
    Fang J, Bjorkan D. A critical approach to noncardiac chest pain: pathophysiology, diagnosis, and treatment. Am J Gastroenterol 2001; 96: 95868.
    Direct Link:
  • 39
    Chambers J, Cooke R, Anggiansah A, Owe W. Effect of omeprazole in patients with chest pain and normal coronary anatomy: initial experience. Int J Cardiol 1998; 65: 515.
  • 40
    Borzecki AM, Pedrosa MC, Prashker MJ. Should noncardiac chest pain be treated empirically? A cost-effectiveness analysis. Arch Intern Med 2000; 160: 84452.